SAN DIEGO - Aethlon Medical, Inc. (NASDAQ:AEMD), a developer of medical products aimed at treating cancer and infectious diseases, has announced a collaboration with Santersus AG to conduct pre-clinical studies on the latter's blood filtration devices. These studies will investigate the potential combined use of Aethlon's Hemopurifier® with Santersus' devices, which are designed to remove harmful Neutrophil Extracellular Traps (NETs) from the blood.
NETs, which can be toxic to tissues and organs, play a role in various medical conditions, including cancer, sepsis, autoimmune diseases, and organ transplant complications. Santersus' NucleoCapture and HemoNucleoCapture devices, which Aethlon will be studying, aim to filter these NETs from the blood.
The Hemopurifier® by Aethlon is a therapeutic device that targets the removal of life-threatening viruses and harmful exosomes from blood and other biological fluids. It has received Breakthrough Device designation from the U.S. Food & Drug Administration (FDA) for use in advanced or metastatic cancer treatment, as well as for life-threatening viruses not addressed with approved therapies.
James Frakes, Interim CEO and CFO of Aethlon, expressed optimism about the upcoming pre-clinical studies and the potential for the technologies to work synergistically, particularly in the fields of oncology and renal transplantation. Scott Maguire, Chairman of Santersus, also highlighted the importance of NETs in cancer progression and the potential benefits of combining the NucleoCapture technology with the Hemopurifier®.
Santersus AG, based in Zurich and London, is a clinical stage company specializing in therapeutic apheresis devices. Its NucleoCapture device has shown the ability to remove over 95% of NETs in a single pass of blood through the device in clinical trials. The company's focus extends to treatments for sepsis, organ transplantation, and neurodegenerative diseases, including Alzheimer's.
The partnership marks a significant step for both companies, potentially paving the way for future collaborations.
The information in this article is based on a press release statement.
InvestingPro Insights
In light of Aethlon Medical, Inc.'s (NASDAQ:AEMD) recent collaboration with Santersus AG, investors may be curious about the company's financial health and market performance. According to InvestingPro, Aethlon Medical holds more cash than debt on its balance sheet, which could provide financial flexibility as it embarks on these new pre-clinical studies. Additionally, the company's Relative Strength Index (RSI) suggests that the stock is currently in oversold territory, which may interest potential investors looking for entry points.
However, it's important to note that Aethlon Medical is quickly burning through cash and analysts do not anticipate the company will be profitable this year. This could be a critical factor for investors to consider, especially in the context of research and development expenses related to the collaboration with Santersus AG.
InvestingPro Data shows a market capitalization of 4.32 million USD, indicating a relatively small player in the biotech industry. The company's revenue for the last twelve months as of Q3 2024 is reported at 0.57 million USD, with an extraordinary revenue growth of 4278.2%. However, this growth figure should be approached with caution, as it may not be sustainable and could reflect a low base effect from previous periods. Aethlon's gross profit margin stands at 100%, but the operating income margin is deeply negative at -2199.15%, highlighting the company's current challenges in generating profitable operations.
For investors seeking a deeper analysis, there are additional InvestingPro Tips available, which can be accessed through the InvestingPro platform. For instance, Aethlon's liquid assets exceed its short-term obligations, which is a positive sign for short-term financial health. However, the company's valuation implies a poor free cash flow yield, and its stock price has performed poorly over the last decade. Moreover, Aethlon does not pay a dividend to shareholders, which may be a consideration for income-focused investors.
To explore these insights further and access a comprehensive list of InvestingPro Tips, investors can visit Investing.com/pro/AEMD. Remember to use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. InvestingPro offers a total of 10 additional tips that could help investors make more informed decisions regarding Aethlon Medical, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.